B38.7 Disseminated coccidioidomycosis

Name of the Condition

• Disseminated coccidioidomycosis

Summary

Disseminated coccidioidomycosis is a severe fungal infection caused by Coccidioides species, where the infection spreads beyond the lungs to other organs or tissues. It represents a progressive form of coccidioidomycosis, often occurring in individuals with weakened immune systems. The condition can involve multiple organ systems, including the skin, bones, joints, or central nervous system, and may present with widespread symptoms.

Causes

The infection originates from inhaling airborne spores of Coccidioides fungi, which are endemic to arid regions like the southwestern United States, Mexico, and parts of Central and South America. After initial lung infection, the fungus can disseminate hematogenously to other sites, particularly in immunocompromised hosts. The fungi thrive in soil and are released during activities that disturb the ground, such as construction or farming.

Risk Factors

• Residence or travel to endemic regions, especially during dry, dusty seasons.
• Occupational exposure to soil (e.g., farmers, construction workers, archaeologists).
• Immunocompromised states, including HIV/AIDS, organ transplantation, or prolonged corticosteroid use.
• Pregnancy, particularly the third trimester.
• Advanced age.

Symptoms

• Fatigue and malaise.
• Cough, chest pain, or shortness of breath (if pulmonary involvement persists).
• Fever, night sweats, or weight loss.
• Skin lesions, nodules, or ulcers.
• Joint pain, swelling, or bone lesions.
• Headache, neck stiffness, or neurological symptoms (if central nervous system is involved).
• Abdominal pain or organ-specific symptoms (e.g., liver, spleen).

Diagnosis

Diagnosis requires clinical evaluation, imaging (e.g., chest X-ray, CT, or MRI to identify organ involvement), and laboratory testing. Cultures or histopathology of affected tissues may confirm Coccidioides species. Serologic tests (e.g., complement fixation) can detect antibodies, while antigen detection or PCR may aid in severe or disseminated cases. Biopsy of lesions or cerebrospinal fluid analysis may be necessary for organ-specific involvement.

Treatment Options

Treatment involves antifungal medications, typically amphotericin B for severe cases, followed by azoles (e.g., fluconazole, itraconazole) for maintenance. Duration depends on disease severity and immune status. Immunocompromised patients may require prolonged therapy. Surgical intervention may be needed for abscesses, bone lesions, or other complications.

Prognosis and Follow-Up

Prognosis varies by immune status and organ involvement; immunocompetent patients often recover with treatment, while immunocompromised individuals may face chronic or recurrent disease. Regular follow-up with imaging and clinical assessments is essential to monitor for recurrence or treatment response. Lifelong suppressive therapy may be necessary in high-risk cases.

Complications

• Chronic pulmonary disease or fibrosis.
• Meningitis or other central nervous system involvement.
• Bone or joint destruction.
• Skin ulcers or disfiguring lesions.
• Organ failure (e.g., liver, spleen) in severe cases.
• Recurrence after treatment discontinuation in immunocompromised hosts.

Lifestyle & Prevention

• Avoid dusty areas in endemic regions, especially during dry seasons.
• Use masks or respirators during soil-disturbing activities.
• Maintain immune health (e.g., manage HIV, avoid unnecessary immunosuppressants).
• Seek prompt medical care for respiratory symptoms after travel to endemic areas.

When to Seek Professional Help

Consult a healthcare provider if you experience persistent respiratory symptoms, unexplained fever, weight loss, or organ-specific symptoms (e.g., headache, joint pain) after exposure to endemic regions. Immunocompromised individuals should seek care immediately for any concerning symptoms.

Tips for Medical Coders

Document the site(s) of dissemination (e.g., skin, bones, CNS) and any underlying immunocompromising conditions, as these impact coding specificity. Ensure clinical correlation with laboratory or imaging results to confirm disseminated disease. Note that B38.7 is used when coccidioidomycosis has spread beyond the lungs, and supporting documentation should reflect multi-organ involvement.